Last reviewed · How we verify
Glycopyrronium MDI 28.8 micrograms — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Glycopyrronium MDI 28.8 micrograms (Glycopyrronium MDI 28.8 micrograms) — Pearl Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Glycopyrronium MDI 28.8 micrograms TARGET | Glycopyrronium MDI 28.8 micrograms | Pearl Therapeutics, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Glycopyrronium MDI 28.8 micrograms CI watch — RSS
- Glycopyrronium MDI 28.8 micrograms CI watch — Atom
- Glycopyrronium MDI 28.8 micrograms CI watch — JSON
- Glycopyrronium MDI 28.8 micrograms alone — RSS
Cite this brief
Drug Landscape (2026). Glycopyrronium MDI 28.8 micrograms — Competitive Intelligence Brief. https://druglandscape.com/ci/glycopyrronium-mdi-28-8-micrograms. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab